The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Open accessAbstract
IMPORTANCE: The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab. OBJECTIVE: To characterize the association of pembrolizumab with tumor response and overall survival among patients with advanced melanoma. DESIGN, SETTINGS, AND PARTICIPANTS: Open-label, multicohort, phase 1b clinical trials (enrollment, December 2011-September 2013). Median duration of follow-up was 21 months. The study was performed in academic medical centers in Australia, Canada, France, and the United States. Eligible patients were aged 18 years and older and had advanced or metastatic melanoma. Data were pooled from 655 enrolled patients (135 from a nonrandomized cohort [n = 87 ipilimumab naive; n = 48 ipilimumab treated] and 520 from randomized cohorts [n = 226 ipilimumab naive; n = 294 ipilimumab treated]). Cutoff dates were April 18, 2014, for safety analyses and October 18, 2014, for efficacy analyses. EXPOSURES: Pembrolizumab 10 mg/kg every 2 weeks, 10 mg/kg every 3 weeks, or 2 mg/kg every 3 weeks continued until disease progression, intolerable toxicity, or investigator decision. MAIN OUTCOMES AND MEASURES: The primary end point was confirmed objective response rate (best overall response of complete response or partial response) in patients with measurable disease at baseline per independent central review. Secondary end points included toxicity, duration of response, progression-free survival, and overall survival. RESULTS: Among the 655 patients (median [range] age, 61 [18-94] years; 405 [62%] men), 581 had measurable disease at baseline. An objective response was reported in 194 of 581 patients (33% [95% CI, 30%-37%]) and in 60 of 133 treatment-naive patients (45% [95% CI, 36% to 54%]). Overall, 74% (152/205) of responses were ongoing at the time of data cutoff; 44% (90/205) of patients had response duration for at least 1 year and 79% (162/205) had response duration for at least 6 months. Twelve-month progression-free survival rates were 35% (95% CI, 31%-39%) in the total population and 52% (95% CI, 43%-60%) among treatment-naive patients. Median overall survival in the total population was 23 months (95% CI, 20-29) with a 12-month survival rate of 66% (95% CI, 62%-69%) and a 24-month survival rate of 49% (95% CI, 44%-53%). In treatment-naive patients, median overall survival was 31 months (95% CI, 24 to not reached) with a 12-month survival rate of 73% (95% CI, 65%-79%) and a 24-month survival rate of 60% (95% CI, 51%-68%). Ninety-two of 655 patients (14%) experienced at least 1 treatment-related grade 3 or 4 adverse event (AE) and 27 of 655 (4%) patients discontinued treatment because of a treatment-related AE. Treatment-related serious AEs were reported in 59 patients (9%). There were no drug-related deaths. CONCLUSIONS AND RELEVANCE: Among patients with advanced melanoma, pembrolizumab administration was associated with an overall objective response rate of 33%, 12-month progression-free survival rate of 35%, and median overall survival of 23 months; grade 3 or 4 treatment-related AEs occurred in 14%. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01295827.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Immune checkpoint blockade with monoclonal antibodies (mAbs) targeting programmed cell death protein 1 (PD-1) provides long-term clinical benefits to nearly 40% of patients with advanced melanoma (1–5).”
From Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients (2021) · cites this paper as [2]
In the citing paper
“Both CTLA-4 and PD-1 act independently as brakes on CD3/CD28-dependent signaling, suggesting that underlying immune responses are required for checkpoint inhibitor treatment to take effect (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“In melanoma, anti-PD-1 treatment was more effective in patients with smaller tumors (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“Both CTLA-4 and PD-1 act independently as brakes on CD3/CD28-dependent signaling, suggesting that underlying immune responses are required for checkpoint inhibitor treatment to take effect (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“For example, patients with smaller tumors or low serum lactate dehydrogenase (LDH) levels at baseline have a better prognosis and are also more likely to respond to anti-PD-1 treatment (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“Patients more likely to benefit from checkpoint immunotherapy include those with tumors demonstrating a high density of somatic mutations, elevated PD-L1 expression and/or are enriched with IFNγ transcriptional profiles (8–13).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [11]
In the citing paper
“The degree of tumor inflammation, as assessed by the presence of type I/II IFN signaling and infiltrating effector T cells, is associated with an improved response to checkpoint immunotherapy (8–11,13).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [11]
In the citing paper
“Anti-PD-1 immunotherapy has shown efficacy in melanoma, but fewer than half of all melanoma patients treated with anti-PD-1 immunotherapy have a prolonged response5.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Self-citationWolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citationTopalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Self-citation
Flagged first, then by citations
Research works printed but not linked: 4
- Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma. Lancet. 2014;384(9948):1109-1117.
- Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002). Lancet Oncol. 2015;16(8):908-918.
- Joseph RW, Elassaiss-Schaap J, Wolchok JD, et al. Baseline tumor size (BTS) and PD-L1 expression are independently associated with clinical outcomes in patients (pts) with metastatic melanoma (MM) treated with pembrolizumab (pembro; MK-3475). Abstract presented at: Society for Melanoma Research 2014 Congress; November 13-16, 2014; Zurich, Switzerland. Pigment Cell Melanoma Res. 2014;27:1188.
- Kluger HM, Sznol M, Callahan MK et al. Survival, response duration and activity by BRAF mutation status in a phase 1 trial of nivolumab (anti-PD-1; BMS-936558,ONO-4538) and ipilimumab concurrent therapy in advanced melanoma (MEL). Abstract presented at: Society for Melanoma Research 2014 Congress; November 13-16, 2014; Zurich, Switzerland. Pigment Cell Melanoma Res. 2014;27:1203.
Cited by
Sorted by citations
Items 201–300 of 1,000
PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
Šmahel, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061331 · Cited by 84
Zhang, X., Ashcraft, K. A., Warner, A. B., Nair, S. K., & Dewhirst, M. W. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2468 · Cited by 89
Zhang, P., Darmon, A., Marill, J., Anesary, N. M., & Paris, S. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s250490 · Cited by 81
Hamid, O., Molinero, L. L., Bolen, C. R., Sosman, J. A., Muñoz‐Couselo, E., Kluger, H. M., McDermott, D. F., Powderly, J. D., Sarkar, I., Ballinger, M. D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3488 · Cited by 82
Self-citationMDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma
Forschner, A., Hilke, F.-J., Bonzheim, I., Gschwind, A., Demidov, G. M., Amaral, T. M. S., Ossowski, S., Rieß, O., Schroeder, C., Martus, P., et al. (2020) · Cancers · doi:10.3390/cancers12030540 · Cited by 81
Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma
Beasley, G. M., Nair, S. K., Farrow, N. E., Landa, K., Selim, M. A., Wiggs, C. A., Jung, S., Bigner, D. D., Kelly, A. T., Gromeier, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002203 · Cited by 80
Peng, S., Chen, S., Hu, W., Mei, J., Zeng, X., Su, T., Wang, W., Chen, Z., Xiao, H., Zhou, Q., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0931 · Cited by 79
Self-citationWang, B., Yin, H., Zhang, Y., Zhao, Q., Wang, H., Wei, J., Meng, L., Xin, Y., & Jiang, X. M. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01073-9 · Cited by 85
Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy
Li, X., Song, W., Shao, C., Shi, Y., & Han, W. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0086-z · Cited by 79
Self-citationMathew, D., Kremer, K. N., Strauch, P., Tigyi, G., Pelanda, R., & Torres, R. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01159 · Cited by 82
Hsueh, E. C., DeBloom, J. R., Lee, J. W. J., Sussman, J. J., Covington, K. R., Middlebrook, B. S., Johnson, C. E., Cook, R. W., Slingluff, C. L., & McMasters, K. M. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0520-1 · Cited by 78
Luke, J. J., Ascierto, P. A., Carlino, M. S., Gershenwald, J. E., Grob, J., Hauschild, A., Kirkwood, J. M., Long, G. V., Mohr, P., Robert, C., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0666 · Cited by 78
Self-citationThe Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer
Tang, Y., Zhang, P., Wang, Y., Wang, J., Su, M., Wang, Y., Zhou, L., Zhou, J., Xiong, W., Zeng, Z., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00604 · Cited by 81
Sullivan, R. J., Atkins, M. B., Kirkwood, J. M., Agarwala, S. S., Clark, J. I., Ernstoff, M. S., Fecher, L. A., Gajewski, T. F., Gastman, B., Lawson, D. H., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0362-6 · Cited by 80
Self-citationLiede, A., Hernandez, R. K., Wade, S. W., Bo, R., Nussbaum, N. C., Ahern, E. S., Dougall, W. C., & Smyth, M. J. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1480301 · Cited by 76
Broman, K. K., Dossett, L. A., Sun, J. X., Eroglu, Z., & Zager, J. S. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1607289 · Cited by 76
Extracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives
Raimondo, S., Pucci, M., Alessandro, R., & Fontana, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072286 · Cited by 79
Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders
Jannin, A., Penel, N., Ladsous, M., Vantyghem, M., & Cao, C. D. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.015 · Cited by 77
Ye, H., Wang, K., Zhao, J., Qi, L., Wang, M., Sun, B., Shen, Y., Liu, H., Pané, S., Chen, X., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c01733 · Cited by 75
Davar, D., Ding, F., Saul, M. I., Sander, C., Tarhini, A. A., Kirkwood, J. M., & Tawbi, H. A. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0279-5 · Cited by 76
Chan, L., Hwang, S. J. E., Byth, K., Kyaw, M., Carlino, M. S., Chou, S., & Fernández‐Peñas, P. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.06.035 · Cited by 75
Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies
Siu, L. L., Ivy, S. P., Dixon, E. L., Gravell, A. E., Reeves, S. A., & Rosner, G. L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3079 · Cited by 75
da Silva, I. P., & Long, G. V. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000405 · Cited by 75
Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer
Grywalska, E., Pasiarski, M., Góźdź, S. S., & Roliński, J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s150817 · Cited by 82
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells
Mukherjee, N., Skees, J., Todd, K. J., West, D. A., Lambert, K. A., Robinson, W. A., Amato, C. M., Couts, K. L., Gulick, R. J. V., MacBeth, M. L., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2646-2 · Cited by 76
Bocanegra, A., Fernández-Hinojal, G., Zuazo, M., Arasanz, H., García-Granda, M. J., Hernandez, C., Ibáñez-Vea, M., Hernández‐Marín, B., Martínez-Aguillo, M., Lecumberri, M. J., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071631 · Cited by 73
Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment
Wohlmuth, C., & Wieser, I. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00614-7 · Cited by 75
Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines
Oladejo, M., Paulishak, W., & Wood, L. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.003 · Cited by 75
Wong, P. F., Wei, W., Gupta, S., Smithy, J. W., Zelterman, D. A., Kluger, H. M., & Rimm, D. L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0675-0 · Cited by 77
Trial watch: immune checkpoint blockers for cancer therapy
Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373237 · Cited by 73
Ahronian, L. G., & Corcoran, R. B. (2017) · Genome Medicine · doi:10.1186/s13073-017-0431-3 · Cited by 67
Memory-like Differentiation Enhances NK Cell Responses to Melanoma
Marín, N. D., Krasnick, B. A., Becker‐Hapak, M., Conant, L., Goedegebuure, S. P., Berrien-Elliott, M. M., Robbins, K. J., Foltz, J. A., Foster, M., Wong, P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0851 · Cited by 72
The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma
Ernst, M. K., & Giubellino, A. (2022) · Biomedicines · doi:10.3390/biomedicines10040822 · Cited by 78
CD8+ T cells modulate autosomal dominant polycystic kidney disease progression
Kleczko, E. K., Marsh, K. H., Tyler, L. C., Furgeson, S. B., Bullock, B., Altmann, C. J., Miyazaki, M., Gitomer, B. Y., Harris, P. C., Weiser‐Evans, M. C. M., et al. (2018) · Kidney International · doi:10.1016/j.kint.2018.06.025 · Cited by 74
Wang, Y., Ma, R., Liu, F., Lee, S. A., & Zhang, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00374 · Cited by 71
Targeting cancer stem cells in the clinic: Current status and perspectives
Annett, S., & Robson, T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.001 · Cited by 76
Cell-Intrinsic Barriers of T Cell-Based Immunotherapy
Ghoneim, H. E., Zamora, A. E., Thomas, P. G., & Youngblood, B. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.10.002 · Cited by 71
Röver, L. K., Gevensleben, H., Dietrich, J., Bootz, F., Landsberg, J., Goltz, D., & Dietrich, D. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.01.016 · Cited by 73
(2022) · doi:10.1016/j.hsr.2021.100010 · Cited by 69
Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?
Renner, A., Burotto, M., & Rojas, C. (2019) · Journal of Global Oncology · doi:10.1200/jgo.19.00142 · Cited by 69
Algazi, A. P., Esteve‐Puig, R., Nosrati, A., Hinds, B. R., Muthukumar, A. H., Nandoskar, P., Ortiz‐Urda, S., Chapman, P. B., & DAUD, A. I. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12644 · Cited by 70
Self-citationFrom immune checkpoints to vaccines: The past, present and future of cancer immunotherapy
Osipov, A., Murphy, A. G., & Zheng, L. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.002 · Cited by 69
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
O’Donnell, J. S., Smyth, M. J., & Teng, M. W. L. (2016) · Genome Medicine · doi:10.1186/s13073-016-0365-1 · Cited by 69
Clinical and molecular insights into BCG immunotherapy for melanoma
Kremenovic, M., Schenk, M., & Lee, D. J. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13037 · Cited by 66
The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era
Spyrou, N., Vallianou, N. G., Kadillari, J., & Dalamaga, Μ. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.008 · Cited by 66
Wang, J., Chmielowski, B., Pellissier, J. M., Xu, R., Stevinson, K. L., & Liu, F. X. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.2.184 · Cited by 66
Self-citationEpigenetic modulation in cancer immunotherapy
Gallagher, S. J., Shklovskaya, E., & Hersey, P. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.006 · Cited by 68
Self-citationTumour mutation status and sites of metastasis in patients with cutaneous melanoma
Adler, N. R., Wolfe, R. S., Kelly, J. W., Haydon, A. M., McArthur, G. A., McLean, C., & Mar, V. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.254 · Cited by 66
Lelliott, E. J., McArthur, G. A., Oliaro, J., & Sheppard, K. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661737 · Cited by 65
Mou, H., Yu, L., Liao, Q., Hou, X., Wu, Y., Cui, Q., Yan, N., Ma, R., Wang, L., Yao, M., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-5021-2 · Cited by 67
Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?
Mittica, G., Genta, S., Aglietta, M., & Valabrega, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071169 · Cited by 66
Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma
Adhikaree, J., Moreno-Vicente, J., Kaur, A. P., Jackson, A. M., & Patel, P. M. (2020) · Cells · doi:10.3390/cells9020263 · Cited by 68
Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy
Boone, C. E., Wang, L., Gautam, A., Newton, I. G., & Steinmetz, N. F. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1739 · Cited by 66
Hollow Mesoporous Manganese Oxides: Application in Cancer Diagnosis and Therapy
Xu, W., Qing, X., Liu, S., Yang, D., Dong, X., & Zhang, Y. (2022) · Small · doi:10.1002/smll.202106511 · Cited by 65
McGuire, H. M., Shklovskaya, E., Edwards, J. J., Trevillian, P., McCaughan, G. W., Bertolino, P., McKenzie, C. A., Gourlay, R., Gallagher, S. J., Groth, B. F. D. S., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2107-7 · Cited by 66
Self-citationImmunosuppressive Roles of Galectin-1 in the Tumor Microenvironment
Huang, Y., Wang, H., Zhao, J., Wu, M., & Shih, T. (2021) · Biomolecules · doi:10.3390/biom11101398 · Cited by 67
Fallon, J. K., Vandeveer, A. J., Schlom, J., & Greiner, J. W. (2017) · Oncotarget · doi:10.18632/oncotarget.16137 · Cited by 64
Isolation of Tumor-Infiltrating Lymphocytes by Ficoll-Paque Density Gradient Centrifugation
Tan, Y. S., & Lei, Y. L. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9167-9_8 · Cited by 63
Lü, J., Li, L., Lan, Y., Liang, Y., & Meng, H. (2019) · Cancer Medicine · doi:10.1002/cam4.2661 · Cited by 63
Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches
Schick, J., Ritchie, R. P., & Restini, C. B. A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223421995854 · Cited by 64
Puzanov, I. J., Ribas, A., Robert, C., Schachter, J., Nyakas, M., DAUD, A. I., Arance, A. M., Carlino, M. S., O'Day, S. J., Long, G. V., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2288 · Cited by 61
Self-citationDeacon, D. C., Smith, E. A., & Judson‐Torres, R. L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.642380 · Cited by 64
Medina, T. M., Chesney, J. A., Kluger, H. M., Hamid, O., Whitman, E. D., Cusnir, M., Thomas, S. S., Wermke, M., Domingo‐Musibay, E., Phan, G. Q., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00765 · Cited by 68
Self-citationBorcherding, N. C., Kolb, R. H., Gullicksrud, J. A., Vikas, P., Zhu, Y., & Zhang, W. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.030 · Cited by 60
Cortellino, S., Quagliariello, V., Delfanti, G., Blaževitš, O., Chiodoni, C., Maurea, N., Mauro, A. D., Tatangelo, F., Pisati, F., Shmahala, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41066-3 · Cited by 66
Cauwels, A., Lint, S. V., Garcin, G., Bultinck, J., Paul, F., Gerlo, S., der Heyden, J. V., Bordat, Y., Catteeuw, D., Cauwer, L. D., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1398876 · Cited by 63
Emerging biomarkers for cancer immunotherapy in melanoma
Axelrod, M. L., Johnson, D. B., & Balko, J. M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.09.004 · Cited by 58
The role of the bacterial microbiome in the treatment of cancer
Yu, Z., Xie, R., You, R., Liu, Y., Chen, X.-Y., Chen, M., & Huang, P.-Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08664-0 · Cited by 57
Seliger, B. (2016) · HLA · doi:10.1111/tan.12898 · Cited by 56
Ocular Toxicity of Targeted Anticancer Agents
Fortes, B. H., Tailor, P. D., & Dalvin, L. A. (2021) · Drugs · doi:10.1007/s40265-021-01507-z · Cited by 60
Boespflug, A. M., Caramel, J., Dalle, S., & Thomas, L. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017708160 · Cited by 57
Atkins, M. B., Hodi, F. S., Thompson, J. A., McDermott, D. F., Hwu, W., Lawrence, D. P., Dawson, N. A., Wong, D. J., Bhatia, S., James, M. L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3436 · Cited by 58
Self-citationAbbott, C. W., Boyle, S. M., Pyke, R. M., McDaniel, L., Levy, É., Navarro, F. C. P., Mellacheruvu, D., Zhang, S. V., Tan, M., Santiago, R., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4314 · Cited by 56
Keller, H. R., Zhang, X., Li, L., Schaider, H., & Wells, J. W. (2017) · Oncotarget · doi:10.18632/oncotarget.18523 · Cited by 55
SOCS1 is a critical checkpoint in immune homeostasis, inflammation and tumor immunity
Bidgood, G. M., Keating, N., Doggett, K., & Nicholson, S. E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1419951 · Cited by 61
Botticelli, A., Zizzari, I. G., Mazzuca, F., Ascierto, P. A., Putignani, L., Marchetti, L., Napoletano, C., Nuti, M., & Marchetti, P. (2016) · Oncotarget · doi:10.18632/oncotarget.12985 · Cited by 57
Diagnosis and Management of Immune Checkpoint Inhibitor Colitis.
Hashash, J. G., Francis, F. F., & Farraye, F. A. (2021) · Europe PMC (PubMed Central) · Cited by 55
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55
Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy
Parakh, S., Cebon, J. S., & Klein, O. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0531 · Cited by 55
Bosisio, F. M., Antoranz, A., Herck, Y. V., Bolognesi, M. M., Marcelis, L., Chinello, C., Wouters, J., Magni, F., Alexopoulos, L. G., Stas, M., et al. (2020) · eLife · doi:10.7554/elife.53008 · Cited by 52
RP1 Combined With Nivolumab in Advanced Anti–PD-1–Failed Melanoma (IGNYTE)
Wong, M. K., Milhem, M. M., Sacco, J. J., Michels, J., In, G. K., Muñoz‐Couselo, E., Schadendorf, D., Beasley, G. M., Niu, J., Chmielowski, B., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-01346 · Cited by 54
Self-citationde Groot, R., van Loenen, M. M., Guislain, A., Nicolet, B. P., Heeren, J. J. F., Verhagen, O. J. H. M., van den Heuvel, M. M., de Jong, J., Burger, P., van der Schoot, C. E., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1648170 · Cited by 57
Rujas, E., Cui, H., Sicard, T., Semesi, A., & Julien, J. (2020) · Nature Communications · doi:10.1038/s41467-020-18828-4 · Cited by 56
Dou, X., Yan, H., Chen, Z., Chao, F., & Li, M. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac006 · Cited by 54
Akkermansia muciniphila: A potential target and pending issues for oncotherapy
Zhao, X., Zhao, J., Li, D., Yang, H. K., Chen, C., Qin, M., Wen, Z., He, Z., & Xu, L. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106916 · Cited by 55
Chen, Q., Li, Y., Wang, X., Zhang, X., Hu, Y., Li, L., Suo, D., Ni, K., Li, Z., Zhan, J., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1542 · Cited by 55
A Rare Case of Pembrolizumab‐Induced Uveitis in a Patient with Metastatic Melanoma
Hanna, K. S. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1839 · Cited by 52
Clinical Development of PD-1 in Advanced Melanoma
Munhoz, R. R., & Postow, M. A. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000299 · Cited by 50
Acquired resistance to cancer immunotherapy
Draghi, A., Chamberlain, C. A., Furness, A. J. S., & Donia, M. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0692-y · Cited by 51
Yao, L., Jia, G., Lu, L., Bao, Y., & Ma, W. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106628 · Cited by 54
GammaTile ® : Surgically targeted radiation therapy for glioblastomas
Gessler, D. J., Ferreira, C., Dusenbery, K. E., & Chen, C. C. (2020) · Future Oncology · doi:10.2217/fon-2020-0558 · Cited by 52
Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
Colen, R. R., Rolfo, C. D., Ak, M., Ayoub, M., Ahmed, S., Elshafeey, N. A., Mamindla, P., Zinn, P. O., Ng, C. S., Vikram, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001752 · Cited by 54
Kreft, S., Gesierich, A., Eigentler, T., Franklin, C., Valpione, S., Ugurel, S., Utikal, J. S., Haferkamp, S., Blank, C. U., Larkin, J., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.05.015 · Cited by 51
Pivotal factors associated with the immunosuppressive tumor microenvironment and melanoma metastasis
Zhang, C., Dang, D., Cong, L., Sun, H., & Cong, X. (2021) · Cancer Medicine · doi:10.1002/cam4.3963 · Cited by 50
Wei, B., Kang, J., Kibukawa, M., Arreaza, G., Maguire, M. G., Chen, L., Qiu, P., Lang, L., Aurora-Garg, D., Cristescu, R., et al. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2022.01.008 · Cited by 51
Response of Advanced Stage Recurrent Lymphoepithelioma-Like Carcinoma to Nivolumab
Kumar, V., Dave, V., Harris, J., & Huang, Y. (2017) · Immunotherapy · doi:10.2217/imt-2017-0067 · Cited by 47
Dmello, C., Zhao, J., Chen, L., Gould, A., Castro, B. A., Arrieta, V. A., Zhang, D. Y., Kim, K.-S., Kanojia, D., Zhang, P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36878-2 · Cited by 49
Self-citationZhou, X., Khan, S. H., Huang, D., & Li, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.938470 · Cited by 48
The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy
Mejía-Guarnizo, L. V., Monroy-Camacho, P. S., Turizo-Smith, A. D., & Rodríguez-García, J. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1298571 · Cited by 48
Ibrahim, T., Mateus, C., Baz, M., & Robert, C. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2219-8 · Cited by 48
Self-citation
Metadata
- Authors
- Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., Gangadhar, T. C., Hersey, P., Dronca, R., Joseph, R. W., Zarour, H., Chmielowski, B., Lawrence, D. P., Algazi, A., Rizvi, N. A., Hoffner, B., Mateus, C., Gergich, K., Lindia, J. A., Giannotti, M., Li, X. N., Ebbinghaus, S., Kang, S. P., & Robert, C.
- Affiliations
- University of California, Los Angeles (US)
- Angeles Clinic and Research Institute (US)
- University of California, San Francisco (US)
- Dana-Farber Cancer Institute (US)
- Memorial Sloan Kettering Cancer Center (US)
- Westmead Hospital (AU)
- Princess Margaret Cancer Centre (CA)
- South Texas Accelerated Research Therapeutics (US)
- The University of Texas MD Anderson Cancer Center (US)
- Moffitt Cancer Center (US)
- Abramson Cancer Center (US)
- The University of Sydney (AU)
- Mayo Clinic (US)
- Mayo Clinic in Florida (US)
- University of Pittsburgh (US)
- Massachusetts General Hospital (US)
- Institut Gustave Roussy (FR)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Ribas, Antoni
- ORCID
- Ribas, Antoni
- Hamid, Omid
- Daud, Adil
- Hodi, F. Stephen
- Wolchok, Jedd D.
- Kefford, Richard
- Joshua, Anthony M.
- Patnaik, Amita
- Hwu, Wen-Jen
- Weber, Jeffrey S.
- Hersey, Peter
- Dronca, Roxana
- Joseph, Richard W.
- Zarour, Hassane
- Chmielowski, Bartosz
- Lawrence, Donald P.
- Algazi, Alain
- Rizvi, Naiyer A.
- Mateus, Christine
- Li, Xiaoyun Nicole
- Robert, Caroline
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-04-19
- Volume
- 315
- Issue
- 15
- Pages
- 1600
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2338494814
- Cited by
- 1,069
- References
- 22
- Citations by year
- 2026: 33 · 2025: 66 · 2024: 67 · 2023: 99 · 2022: 63 · 2021: 123 · 2020: 139 · 2019: 139 · 2018: 145 · 2017: 153 · 2016: 39
- FWCI
- 85.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- pembrolizumab, advanced melanoma, metastatic melanoma, anti-PD-1 therapy, anti-PD-1 monoclonal antibody, objective response rate, overall survival, progression-free survival, duration of response, ipilimumab, immune checkpoint inhibitors, treatment-naive patients, treatment-emergent adverse events, immune-related adverse events, immune-related pneumonitis, immune-related colitis
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Algorithms, Antibodies, Monoclonal, Antineoplastic Agents, Drug Administration Schedule, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Survival Rate, Treatment Outcome, Disease Progression, Disease-Free Survival, Young Adult, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
